Keywords: roche, avastin, fails, show, overall, survival, bevacizumab

Roche's Avastin fails to show overall survival

Article | 28 April 2008

Print This

Roche's Avastin (bevacizumab) failed to show an overall survival benefit in a European lung cancer trial. The Swiss drug major's $4.1 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in